GH Pitié-Salpêtrière-Charles Foix
Welcome,         Profile    Billing    Logout  
 4 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Spano, Jean-Philippe
BFR-ESS, NCT03624244: Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients with Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

Recruiting
2
40
Europe
Aromatase Inhibitors, ANASTRAZOLE, ARIMIDEX, AROMASINE, EXEMESTANE, FEMARA, LETROZOLE
Centre Leon Berard
Low Grade Endometrial Stromal Sarcoma
01/28
01/31
INJECTABL-1, NCT05688280 / 2022-000176-19: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Active, not recruiting
1/2
42
Europe, US
1.0% IP-001 for Injection, IP-001
Immunophotonics, Inc., Immunophotonics Inc.
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
02/25
02/25
KEYNOTE-E72, NCT06016920: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Recruiting
1/2
51
Europe, RoW
VB10.16, Pembrolizumab, KEYTRUDA®
Nykode Therapeutics ASA, Merck Sharp & Dohme LLC
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
09/27
01/28
IDeATIon, NCT03706625: Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment

Completed
N/A
201
Europe
Assistance Publique - Hôpitaux de Paris
Non Hodgkin Lymphoma, Non Small Cell Lung Cancer, Glioma
07/23
07/23
REPARP, NCT05378204: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Recruiting
N/A
120
Europe
Main study:, Sub-study:
Institut Claudius Regaud, Artios Pharma Ltd
Breast Cancer
01/27
06/27
TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting
N/A
500
Europe, RoW
Data collection and quality of life questionnaire
Centre Leon Berard
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation
06/25
06/25
ICRG0101, NCT04273542: Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening

Active, not recruiting
N/A
1100
Europe
liquid biopsy
Centre Jean Perrin, International Cancer Research Group, Institut Max Planck d'optique quantique
Breast Cancer Female, BRCA1 Mutation, BRCA2 Mutation
05/29
05/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Spano, Jean-Philippe
BFR-ESS, NCT03624244: Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients with Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

Recruiting
2
40
Europe
Aromatase Inhibitors, ANASTRAZOLE, ARIMIDEX, AROMASINE, EXEMESTANE, FEMARA, LETROZOLE
Centre Leon Berard
Low Grade Endometrial Stromal Sarcoma
01/28
01/31
INJECTABL-1, NCT05688280 / 2022-000176-19: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Active, not recruiting
1/2
42
Europe, US
1.0% IP-001 for Injection, IP-001
Immunophotonics, Inc., Immunophotonics Inc.
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
02/25
02/25
KEYNOTE-E72, NCT06016920: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Recruiting
1/2
51
Europe, RoW
VB10.16, Pembrolizumab, KEYTRUDA®
Nykode Therapeutics ASA, Merck Sharp & Dohme LLC
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
09/27
01/28
IDeATIon, NCT03706625: Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment

Completed
N/A
201
Europe
Assistance Publique - Hôpitaux de Paris
Non Hodgkin Lymphoma, Non Small Cell Lung Cancer, Glioma
07/23
07/23
REPARP, NCT05378204: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Recruiting
N/A
120
Europe
Main study:, Sub-study:
Institut Claudius Regaud, Artios Pharma Ltd
Breast Cancer
01/27
06/27
TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting
N/A
500
Europe, RoW
Data collection and quality of life questionnaire
Centre Leon Berard
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation
06/25
06/25
ICRG0101, NCT04273542: Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening

Active, not recruiting
N/A
1100
Europe
liquid biopsy
Centre Jean Perrin, International Cancer Research Group, Institut Max Planck d'optique quantique
Breast Cancer Female, BRCA1 Mutation, BRCA2 Mutation
05/29
05/29

Download Options